Switzerland's Tecan 2025 adjusted EPS beats estimates as cost focus outweighs sales decline

Tecan AG

16/03/2026 05:28

Overview

Switzerland laboratory automation firm's 2025 sales declined 1.6% in local currencies

Adjusted EPS for 2025 beat analyst expectations

Company launched transformation program and repurchased shares worth CHF 24.8 mln

Outlook

Tecan expects 2026 sales to rise in the low single-digit percentage range in local currencies

Company forecasts 2026 adjusted EBITDA margin at 15.5-16.5% of sales, including FX and tariff headwinds

Tecan maintains medium-term ambition for CHF 1 bln sales and 20% adjusted EBITDA margin by 2028

Result Drivers

FX AND TARIFF HEADWINDS - Profitability was significantly reduced by adverse foreign exchange effects and tariffs, partly offset by cost-reduction measures and operational improvements

LIFE SCIENCES FUNDING UNCERTAINTY - Life Sciences segment sales were impacted by budget uncertainty and volatile public funding, particularly in the US and China

PARTNERING BUSINESS MIX - Partnering Business margins improved due to a positive product mix and strong cost control, despite weak demand for life science instrumentation

Company press release: ID:nGNE4cWHQQ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Adjusted EPS
Beat
CHF 6.87
CHF 5.78 (7 Analysts)
FY Adjusted Net Income
CHF 87 mln
FY Adjusted EBITDA
CHF 142.10 mln
FY Adjusted EBITDA Margin
16.10%


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)